• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Harmony Biosciences Holdings Inc.

    2/25/25 4:10:50 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRMY alert in real time by email
    S-8 1 tmb-20250225xs8.htm S-8

    As filed with the United States Securities and Exchange Commission on February 25, 2025

    Registration No. 333-

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549


    FORM S-8

    Registration Statement

    Under

    The Securities Act of 1933


    HARMONY BIOSCIENCES HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)


    ​

    ​

    ​

    ​

    ​

    Delaware

    82-2279923

    (State or other jurisdiction of

    (I.R.S. Employer

    incorporation or organization)

    Identification No.)

    630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA

    19462

    (Address of Principal Executive Offices)

    (Zip Code)

    ​

    ​

    (484) 539-9800

    (Registrant’s telephone number, including area code)

    ​


    2020 Incentive Award Plan

    2020 Employee Stock Purchase Plan

    (Full title of the plan)

    ​

    Jeffrey M. Dayno

    President, Chief Executive Officer and Director

    630 W. Germantown Pike, Suite 215

    Plymouth Meeting, Pennsylvania 19462

    (484) 539-9800

    (Name, address and telephone number, including area code, of agent for service)


    Copies to:

    Christopher D. Lueking, Esq.

    Jonathan E. Sarna, Esq.

    Latham & Watkins LLP

    330 North Wabash Avenue, Suite 2800

    Chicago, Illinois 60611

    Telephone (312) 876-7700

    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    ​

    ​

    ​

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

    ​

    ​

    Emerging growth company

    ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    ​

    ​

    ​

    ​


    ​

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is filed by Harmony Biosciences Holdings, Inc. (the “Registrant”) for the purpose of registering (i) 2,285,795 additional shares of the Registrant’s common stock, par value $0.00001 per share (the “Common Stock”) under the Registrant’s 2020 Incentive Award Plan (the “2020 Incentive Award Plan”) and (ii) 571,449 additional shares of Common Stock under the Registrant’s 2020 Employee Stock Purchase Plan (the “2020 ESPP” and, together with the 2020 Incentive Award Plan, the “Plans”).

    ​

    In accordance with General Instruction E of Form S-8, the contents of the prior Registration Statements on Form S-8 (Registration Nos. 333-248243, 333-263077, 333-271570 and 333-277269) (the “Prior Registration Statements”) previously filed with the Securities and Exchange Commission (the “Commission”) are incorporated by reference to the extent not modified or superseded by the Prior Registration Statements, by the information included herein or by any subsequently filed document that is incorporated by reference in this Registration Statement or the Prior Registration Statements.

    ​

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1.Plan Information.

    Not required to be filed with this Registration Statement.

    Item 2.Registrant Information and Employee Plan Annual Information.

    Not required to be filed with this Registration Statement.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.

    Not required to be filed with this Registration Statement.

    Item 4.Description of Securities.

    Not required to be filed with this Registration Statement.

    Item 5.Interests of Named Experts and Counsel.

    Not required to be filed with this Registration Statement.

    Item 6.Indemnification of Directors and Officers.

    Not required to be filed with this Registration Statement.

    Item 7.Exemption from Registration Claimed.

    Not required to be filed with this Registration Statement.


    ​

    Item 8.Exhibits.

    The following documents are filed as exhibits to this Registration Statement:

    ​

    ​

        

        

        

        

        

        

        

        

     

    ​

    ​

    ​

    ​

    Incorporated by Reference

    ​

    ​

    ​

    Exhibit
    Number

        

    Description

        

    Schedule
    Form

        

    Exhibit

        

    Filing
    Date

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.1

    ​

    Harmony Biosciences Holdings, Inc. 2020 Incentive Award Plan.

    ​

    S-8

    ​

    10.2

    ​

    August 21, 2020

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.2

    ​

    Harmony Biosciences Holdings, Inc. 2020 Employee Stock Purchase Plan.

    ​

    S-1/A

    ​

    10.7

    ​

    August 11, 2020

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.3

    ​

    First Amendment to the Harmony Biosciences Holdings, Inc. 2020 Incentive Award Plan, dated March 24, 2022.

    ​

    10-K

    ​

    10.3

    ​

    February 21, 2023

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    5.1*

    ​

    Opinion of Latham & Watkins LLP.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    23.1*

    ​

    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    23.2*

    ​

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    24.1*

    ​

    Power of Attorney (included on the signature page of this Form S-8).

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    107*

    ​

    Filing Fee Table

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    * Filed herewith.

    Item 9.Undertakings.

    (a)The undersigned registrant hereby undertakes:
    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i)To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    Provided however, That: Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained


    ​

    in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement; and 

    (2)That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

    ​


    ​

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Plymouth Meeting, State of Pennsylvania, on the 25th day of February, 2025.

    ​

    HARMONY BIOSCIENCES HOLDINGS, INC.

    ​

    ​

    ​

    By:

    /s/ Jeffrey M. Dayno

    ​

    Name:

    Jeffrey M. Dayno

    ​

    Title:

    President, Chief Executive Officer and Director

    ​


    ​

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jeffrey M. Dayno and Sandip Kapadia, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, increasing the number of securities for which registration is sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

    ​

    ​

    Signature

    ​

    Title

    ​

    Date

    ​

    ​

    ​

    ​

    ​

    /s/ Jeffrey M. Dayno

    ​

    President, Chief Executive Officer and Director

    ​

    February 25, 2025

    Jeffrey M. Dayno

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Sandip Kapadia

    ​

    Chief Financial Officer and Chief Administrative Officer (Principal

    ​

    February 25, 2025

    Sandip Kapadia

    ​

    Financial Officer and Principal Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Jeffrey S. Aronin

    ​

    Chairman of the Board

    ​

    February 25, 2025

    Jeffrey S. Aronin

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Peter Anastasiou

    ​

    Director

    ​

    February 25, 2025

    Peter Anastasiou

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Antonio Gracias

    ​

    Director

    ​

    February 25, 2025

    Antonio Gracias

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ R. Mark Graf

    ​

    Director

    ​

    February 25, 2025

    R. Mark Graf

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Juan A. Sabater

    ​

    Director

    ​

    February 25, 2025

    Juan A. Sabater

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Gary Sender

    ​

    Director

    ​

    February 25, 2025

    Gary Sender

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Linda Szyper

    ​

    Director

    ​

    February 25, 2025

    Linda Szyper

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Andreas Wicki

    ​

    Director

    ​

    February 25, 2025

    Andreas Wicki

    ​

    ​

    ​

    ​

    ​


    Get the next $HRMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HRMY

    DatePrice TargetRatingAnalyst
    7/21/2025$48.00Buy
    Truist
    7/10/2025$33.00Neutral
    Goldman
    6/2/2025$61.00Outperform
    Oppenheimer
    2/11/2025$55.00Buy
    Deutsche Bank
    12/17/2024$75.00Buy
    H.C. Wainwright
    10/10/2024Outperform
    Raymond James
    9/10/2024$56.00Buy
    UBS
    6/21/2024$48.00Buy
    Citigroup
    More analyst ratings

    $HRMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Kapadia Sandip exercised 20,000 shares at a strike of $29.03 and sold $790,896 worth of shares (20,000 units at $39.54) (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    12/9/25 4:10:06 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Kapadia Sandip sold $119,945 worth of shares (3,427 units at $35.00), closing all direct ownership in the company (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    11/25/25 4:10:07 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Kapadia Sandip converted options into 45,000 shares and covered exercise/tax liability with 24,039 shares (SEC Form 4)

    4 - Harmony Biosciences Holdings, Inc. (0001802665) (Issuer)

    10/2/25 4:05:07 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    SEC Filings

    View All

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    12/12/25 4:25:44 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    12/5/25 4:30:21 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Harmony Biosciences Holdings Inc.

    144 - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    11/21/25 4:46:13 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

    Data presented at the 2025 American Epilepsy Society Annual Meeting Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the presentation of initial open-label extension (OLE) data from the company's ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome (DS), which showed clinically meaningful reductions in seizure activity in participants with DS along with a favorable benefit-risk profile. The data from poster #3.353 will be presented at the American Epilepsy Society (AES) Annual Meeting in Atlanta, Ga., on Monday, December 8, from 12:00 pm – 1:45 pm ET. Data from the eighteen participants in the OLE trial with at

    12/8/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced that it will highlight new open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2025 American Epilepsy Society (AES) Annual Meeting being held December 5 – December 9, 2025, in Atlanta, GA. The ARGUS trial is currently enrolling, and more information can be found at argustrial.com. The posters will be on display on Monday, December 8, from 8:00 am - 2:00 pm ET. Poster presentation details are listed below: Abstract Title: EPX-100 as Adjunctive Therapy in Patients With Dravet Syndrome: Preliminary Res

    12/2/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

    New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced positive results from its pivotal bioequivalence (BE) study evaluating pitolisant gastro-resistant (GR) formulation. With positive findings from both the pivotal BE and dosing optimization studies, Harmony is on track to submit a New Drug Application (NDA) for pitolisant GR in early 2026, targeting a PDUFA date in Q1 2027. With utility patent applications filed for pitolisant GR with potential exclusivity to 2044, Harmony is well positioned to extend the pitolisant franchise into th

    11/24/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Harmony Biosciences with a new price target

    Truist initiated coverage of Harmony Biosciences with a rating of Buy and set a new price target of $48.00

    7/21/25 8:34:40 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Harmony Biosciences with a new price target

    Goldman resumed coverage of Harmony Biosciences with a rating of Neutral and set a new price target of $33.00

    7/10/25 8:55:45 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Harmony Biosciences with a new price target

    Oppenheimer resumed coverage of Harmony Biosciences with a rating of Outperform and set a new price target of $61.00

    6/2/25 8:52:53 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Leadership Updates

    Live Leadership Updates

    View All

    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark Therapeutics, where he led the commercial launch of a novel gene therapy to treat an inherited form of blindness, expanded its therapeutic platform to larger disease areas, and acquired new technologies and assets through business developm

    4/3/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), today announced the appointment of Adam Zaeske as Executive Vice President and Chief Commercial Officer (CCO), effective March 31, 2025. The company's current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry, building teams and transforming organizations in both the U.S. and Europe. He has broad functional experience spanning commercial strategy and operations, sales, marketing, market access, new product planning and finance. At Harmony, Zaeske will be responsible for leading the company's commercial organization, setting commercial strate

    3/24/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HARMONY BIOSCIENCES APPOINTS JEFFREY M. DAYNO, MD AS INTERIM CEO AND EXPANDS ROLE OF JEFF ARONIN TO EXECUTIVE CHAIRMAN

    PLYMOUTH MEETING, Pa., Jan. 6, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that John C. Jacobs is stepping down as President and Chief Executive Officer and a member of the Board of Directors to pursue another opportunity. The Harmony Board of Directors has named Jeffrey M. Dayno, MD, Harmony's Executive Vice President and Chief Medical Officer, as interim CEO effective immediately. Jeff Aronin, Harmony's founder and Board chairman, will continue to lead the Board of Directors as well as

    1/6/23 4:39:00 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 7:06:51 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/13/24 5:06:22 PM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Harmony Biosciences Holdings Inc. (Amendment)

    SC 13G/A - Harmony Biosciences Holdings, Inc. (0001802665) (Subject)

    2/9/24 9:03:03 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HRMY
    Financials

    Live finance-specific insights

    View All

    Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

    WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve 8,100 Average Patients in Q3 2025 Strong Cash Generation of $106M with $778M On Balance Sheet at end of Q3 2025 Pitolisant HD IND submitted; On Track to Initiate Phase 3 Trials in Narcolepsy and Idiopathic Hypersomnia in Q4 2025 Potential Best-In-Class Orexin 2 Agonist (BP1.15205) On Track to Dose First Subject in Q4 2025; Phase 1 Clinical Data in 2026 Late-Stage Catalyst-Rich Pipeline Advances with up to Five Phase 3 Programs by Year End Conference Call and Webcast Today at 8:30 a.m. ET Harmony Biosciences Holdings, In

    11/4/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

    Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX® (pitolisant) franchise delivered net revenue of approximately $239M in Q3 2025, representing 29% year-over-year revenue growth These results were driven by the highest ever quarterly increase in average number of patients of approximately 500 for the quarter, reaching 8,100 average patients in Q3 2025, accelerating the trajectory toward potential blockbuster status for WAKIX in narcolepsy The company is increasing its 2025 revenue guidance to $845-$865 million from the previous range of $820-$860 million Harmony to report full Q3 2025 earnings an

    10/23/25 8:05:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

    WAKIX® (pitolisant) Franchise Continues Strong Growth with Net Revenue of $200.5M for Q2 2025 (+16% YoY Growth); Increases Average Patients by 400 to Achieve 7,600 Average Patients in Q2 2025 Phase 3 RECONNECT Study in Fragile X Syndrome (FXS) Designed to Confirm Positive Findings from the Phase 2/3 CONNECT Study; Opportunity to Address Unmet Needs of 80,000 Patients with FXS On Track to Begin First-in-Human Clinical Trial with BP1.15205, a Potential Best-In-Class Orexin-2 Agonist, in 2H 2025 Initiation of Next-Generation Pitolisant HD Phase 3 Registrational Trials in Narcolepsy & Idiopathic Hypersomnia in Q4 2025; Both Indications Targeted for PDUFA in 2028 Conference Call

    8/5/25 7:30:00 AM ET
    $HRMY
    Biotechnology: Pharmaceutical Preparations
    Health Care